Accumulated Other Comprehensive Income (Loss), Net of Tax of Revance Therapeutics, Inc. from 31 Dec 2014 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Revance Therapeutics, Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD history and change rate from 31 Dec 2014 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 30 Sep 2024 was $72,000.
Source SEC data
View on sec.gov
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

Revance Therapeutics, Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $72,000 +$85,000 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $26,000 +$35,000 +57% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $25,000 +$100,000 +80% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $14,000 +$388,000 31 Dec 2023 10-Q 07 Nov 2024 2024 Q3
Q3 2023 $13,000 +$447,000 +97% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $61,000 +$325,000 +84% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $125,000 -$66,000 -112% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $374,000 -$356,000 -1978% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $460,000 -$457,000 -15233% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $386,000 -$384,000 -19200% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $59,000 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $18,000 -$18,000 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $3,000 -$3,000 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $2,000 -$119,000 -102% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q4 2020 $0 -$3,000 -100% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $0 -$42,000 -100% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $117,000 +$1,000 +0.86% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $524,000 +$454,000 +649% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $3,000 +$11,000 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $42,000 +$175,000 30 Sep 2019 10-Q 04 Nov 2019 2019 Q3
Q2 2019 $116,000 +$340,000 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $70,000 +$346,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $8,000 -$8,000 31 Dec 2018 10-K 26 Feb 2020 2019 FY
Q3 2018 $133,000 -$90,000 -209% 30 Sep 2018 10-Q 02 Nov 2018 2018 Q3
Q2 2018 $224,000 -$110,000 -96% 30 Jun 2018 10-Q 03 Aug 2018 2018 Q2
Q1 2018 $276,000 -$178,000 -182% 31 Mar 2018 10-Q 09 May 2018 2018 Q1
Q4 2017 $0 +$45,000 31 Dec 2017 10-K 28 Feb 2019 2018 FY
Q3 2017 $43,000 -$59,000 -369% 30 Sep 2017 10-Q 03 Nov 2017 2017 Q3
Q2 2017 $114,000 -$262,000 -177% 30 Jun 2017 10-Q 04 Aug 2017 2017 Q2
Q1 2017 $98,000 -$284,000 -153% 31 Mar 2017 10-Q 09 May 2017 2017 Q1
Q4 2016 $45,000 -$5,000 -12% 31 Dec 2016 10-K 02 Mar 2018 2017 FY
Q3 2016 $16,000 +$6,000 +60% 30 Sep 2016 10-Q 04 Nov 2016 2016 Q3
Q2 2016 $148,000 +$160,000 30 Jun 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 $186,000 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 $40,000 -$40,000 31 Dec 2015 10-K 28 Feb 2017 2016 FY
Q3 2015 $10,000 30 Sep 2015 10-Q 10 Nov 2015 2015 Q3
Q2 2015 $12,000 30 Jun 2015 10-Q 07 Aug 2015 2015 Q2
Q4 2014 $0 31 Dec 2014 10-K 04 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.